First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients. Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in complete depletion of...
Hence then, the article about magicrna s first in human clinical data demonstrating feasibility of in vivo car t therapy in systemic lupus erythematosus published in the new england journal of medicine was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine. )
Also on site :
- UN renews Sudan ceasefire appeal over ‘unimaginable suffering’ of civilians
- Central African Republic election: Who’s running and what’s at stake?
- Israeli forces continue ceasefire violations with attacks across Gaza